Lanthanum Carbonate Patent Expiration
Lanthanum Carbonate is Used for lowering serum phosphate levels in patients with end stage renal disease. It was first introduced by Takeda Pharmaceuticals Usa Inc
Lanthanum Carbonate Patents
Given below is the list of patents protecting Lanthanum Carbonate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fosrenol | US8980327 | Capsule and powder formulations containing lanthanum compounds | Dec 01, 2030 | Takeda Pharms Usa |
| Fosrenol | US9023397 | Capsule and powder formulations containing lanthanum compounds | Dec 01, 2030 | Takeda Pharms Usa |
| Fosrenol | US7381428 | Stabilized lanthanum carbonate compositions |
Aug 26, 2024
(Expired) | Takeda Pharms Usa |
| Fosrenol | US7465465 | Pharmaceutical formulation comprising lanthanum compounds |
Aug 26, 2024
(Expired) | Takeda Pharms Usa |
| Fosrenol | US5968976 | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
Oct 26, 2018
(Expired) | Takeda Pharms Usa |
Lanthanum Carbonate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lanthanum Carbonate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Lanthanum Carbonate (FosrenolĀ®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis | Universitair Ziekenhuis Brussel | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |